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OBJECTIVES The goal of this study was to assess whether endothelial dysfunction occurs in the forearm
venous capacitance bed of patients with chronic heart failure (CHF) and to determine the role
of nitric oxide (NO) in modulating venous tone.
BACKGROUND Control of venous tone is crucially important in CHF. More than 70% of blood volume lies
in the venous capacitance beds. Therefore, small changes in venous tone may markedly affect
cardiac filling pressures and cardiac output.
METHODS Venous tone was measured using radionuclide forearm venous plethysmography in 24
patients with CHF and 16 age-matched controls. The effect of basal NO activity on venous
tone was assessed by infusing N-monomethyl-L-arginine 12 mg/min and stimulated NO
using carbachol 15 mg/min. Brachial artery flow-mediated dilation was assessed by ultrasonic
wall-tracking.
RESULTS Blockade of basal NO release caused a significant and similar venoconstriction in patients
(9.6 6 1.8%, p , 0.01) and controls (6.6 6 1.7%, p , 0.01). Carbachol-induced venodilation
was significant and similar in patients (36.8 6 3.9%, p , 0.001) and controls (40.7 6 3.9%,
p , 0.001). Brachial artery flow-mediated dilation was impaired in patients compared with
controls (2.0 6 0.6% vs. 7.5 6 2.5%, p , 0.01).
CONCLUSIONS Our data indicate that, despite marked impairment of the function of the arterial endothe-
lium, there is preservation of both basal and stimulated NO release in the forearm venous
capacitance bed. This may provide important insights into mechanisms of endothelial
dysfunction in CHF and the potential for novel therapy. (J Am Coll Cardiol 2001;37:
1062–8) © 2001 by the American College of Cardiology
Endothelial dysfunction has been demonstrated in conduit
arteries and in resistance vessels in chronic heart failure
(CHF) (1–4) and is mainly a consequence of reduced
bioavailable nitric oxide (NO) (5). Endothelial dysfunction
may contribute to increased systemic vascular resistance
(6,7) and to exercise limitation by reducing skeletal muscle
perfusion (8,9). There may also be an adverse impact on
ventriculoarterial coupling via its effects on large artery
stiffness (10).
In addition to increased arterial tone, there is also
increased venous tone in untreated CHF (11,12). This has
important hemodynamic consequences. Since more than
70% of blood volume lies in the venous capacitance system,
it is apparent that relatively modest changes in venous tone
may translocate large volumes of blood to or from the
central compartment. Neural and neurohumoral factors
undoubtedly contribute to the increased venous tone, but
the direct role of the endothelium has not been evaluated
(13,14). Work in conduit veins, such as the dorsal hand
vein, suggested that the venous endothelium had little
influence on venous tone (15). However, the vast majority of
blood volume lies in the small veins and venules that make
up the venous capacitance beds. We recently demonstrated
in healthy subjects that carbachol caused a dose-dependent
(maximum .40%) venodilation of the forearm venous
capacitance bed, and blockade of basal NO release with
N-monomethyl-L-arginine (L-NNMA) caused a 10%
venoconstriction (16). It is not known whether NO release
occurs in capacitance veins in CHF. Dysfunction of the
venous endothelium in CHF would have the potential to
contribute to reduced venous capacitance (and, therefore,
elevated venous tone). We, therefore, investigated whether
NO release occurs in the forearm venous capacitance bed in
patients with CHF.
METHODS
Subjects. Twenty-four patients with clinical features of
CHF who had been referred to the University Hospital of
Wales were studied. All patients had left ventricular ejection
fraction measured by radionuclide ventriculography of
#35% and were on stable medical therapy for $2 months
From the *Department of Cardiology, University of Wales College of Medicine,
Cardiff, United Kingdom; and the †Department of Medical Physics and Clinical
Engineering, University Hospital of Wales, Cardiff, United Kingdom. Supported by
funding from the British Heart Foundation.
Manuscript received June 21, 2000; revised manuscript received November 3, 2000,
accepted December 12, 2000.
Journal of the American College of Cardiology Vol. 37, No. 4, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01142-1
with diuretics and angiotensin-converting enzyme (ACE)
inhibitors. Sixteen healthy volunteers with no risk factors for
cardiovascular disease, a normal cardiovascular examination
and a normal electrocardiogram were recruited as control
subjects. None of the patients or controls was taking
antioxidant vitamin supplements. All subjects gave written
informed consent, and the study was approved by the local
research ethics committee.
Study protocol. The investigations were performed at the
University Hospital of Wales (Cardiff) in a temperature-
controlled laboratory (22 to 24°C). All studies were per-
formed with the subject having fasted and abstained from
caffeine-containing drinks for at least 6 h previously. Di-
uretics were withheld on the morning of the study, but other
drugs were continued as normal.
Measurement of venous tone. Venous tone was assessed
in the forearm capacitance bed by radionuclide venous
plethysmography (17,18). This technique involves labeling
of red blood cells with 99mtechnetium. At least 90% of the
injected isotope is confined to the intravascular space;
therefore, forearm radioactive counts are proportional to
forearm blood volume. Since the vast majority of blood in
the peripheral circulation is contained within the veins
(19–21), changes in counts reflect changes in venous vol-
ume. Construction of a venous volume/pressure relation
allows assessment of venous tone. A parallel shift of the
volume/pressure relation implies a change in venous tone.
The slope of the regression line obtained from the volume/
pressure relation is related to venous compliance. We, and
others, have previously validated this technique (16,22–24).
Importantly, we have shown that the position of the
volume/pressure relation is not altered by large changes in
arterial inflow (16).
A cannula was inserted into the antecubital fossa of
the dominant arm. Stannous fluoride (0.03 ml/kg) was
injected intravenously. Red cells were then labeled using a
quasi in vivo method by mixing 5 ml of the subjects blood
with 750 MBq of 99mtechnetium pertechnetate in a syringe
for 10 min. This was then reinjected through the cannula 20
to 40 min after the stannous injection.
A sphygmomanometer was placed around the nondomi-
nant upper arm. The forearm was positioned comfortably
on the face of a 20-cm field-of-view gamma camera
equipped with a low-energy super-high sensitivity parallel-
hole collimator and with an integrated computer system
(Elscint Apex 215 M). Images of the forearm were contin-
uously acquired in 10-s frames. The cuff was inflated at 60-s
intervals to produce venous occlusion pressures of 10, 20
and 30 mm Hg.
After acquisition, a region of interest was drawn around
the forearm image. The counts in the region of interest were
acquired in the final 30 s of each 60-s interval. The count
obtained with no occluding pressure was arbitrarily taken to
represent resting forearm blood volume. All subsequent read-
ings were expressed as a percentage of this value. Measures of
scintigraphic vascular volumes (in percent units) at 0, 10, 20
and 30 mm Hg were used to construct venous volume/pressure
plots. The data were corrected for physical decay.
After labeling of red cells as described above, a 27-gauge
unmounted steel needle (Cooper’s Engineering, Birming-
ham, United Kingdom) was sealed with dental wax to an
epidural cannula and inserted into the brachial artery of the
nondominant arm. The arm was then positioned on the
gamma camera. To minimize the amount of free circulating
99mtechnetium, imaging was commenced at least 30 min
after initial labeling. Baseline measurements were per-
formed at least 4 min after commencing infusion of 0.9%
saline (1 ml/min). A venous volume/pressure relation was
recorded by sequential incremental inflation of the upper
arm cuff as described above. One minute after deflation of
the cuff, a further volume/pressure relation was recorded.
Stimulated and basal NO release. Stimulated NO activity
was assessed by evaluating the effect of an intraarterial
infusion of carbachol (Martindale Pharmaceuticals, Rom-
ford, United Kingdom) at a concentration of 15 mg/ml at a
rate of 1 ml/min. After 4 min, a venous volume/pressure
relation was performed. Saline was again infused until the
count rate had returned to its resting value and a third
volume/pressure relation performed during saline infusion.
Basal NO activity was next assessed by measuring the
effect of intraarterial L-NMMA (Clinalfa, La¨ufelfingen,
Switzerland), an inhibitor of nitric oxide synthase (NOS),
which was infused in a concentration of 12 mg/ml at a rate
of 1 ml/min. After 10 min of infusion, a venous volume/
pressure relation was obtained.
To allow assessment of the relative contribution of NO to
the carbachol-stimulated response, carbachol (24 mg/ml)
and L-NMMA (30 mg/ml) were coinfused each at a rate of
0.5 ml/min. After 4 min a further volume/pressure relation
was performed.
Measurement of arterial endothelial function. Conduit
artery endothelial function was assessed by measurement of
the endothelial response to increased shear stress. Changes
in brachial artery diameter in response to reactive hyperemia
were measured noninvasively using a high-resolution ultra-
sonic wall-tracking system (Vadirec Wall-Track System,
Medical Systems, Arnhem, The Netherlands, resolution 6
3 mm) as previously described and validated by us (1).
Subjects rested supine with their arm held outstretched on a
pneumatic cushion. Baseline measurements of internal bra-
chial artery diameter and blood pressure were taken after
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
CHF 5 chronic heart failure
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$10 min of supine rest. Blood pressure was measured
noninvasively using photoplethysmography (Finapres,
Ohmeda, Madison, Wisconsin) with a cuff on the middle
finger of the arm being studied. The brachial artery was
imaged using a 7.5 MHz transducer.
Reactive hyperemia was produced by releasing a pediatric
sphygmomanometer wrist cuff inflated to systolic pressure
plus 50 mm Hg for 5 min. Internal brachial artery diameter
was remeasured 60 s after cuff release.
Data analysis. FOREARM VENOUS TONE. Venous volume/
pressure plots were constructed for each stage in each
subject. Unstressed venous volume was defined as the
intercept on the volume (y) axis. Resting unstressed venous
volume in each subject was calculated as the mean of the
three unstressed venous volumes during infusion of normal
saline. Parallel changes in unstressed venous volume reflect
changes in venous tone. The slope of the volume/pressure
relation reflects compliance of the veins involved. Increases in
venous tone are expressed as percentage of venoconstriction,
and decreases in venous tone as percentage of venodilation.
Figure 1 is an example of volume/pressure plots obtained.
Arterial endothelial function. Results are expressed as
percentage of change in diameter from baseline.
Statistics. Data are expressed as mean 6 SEM. Statistical
analysis was performed using a specialist data analysis
package (SPSS version 10). Analysis was performed utiliz-
ing one-way analysis of variance (ANOVA) and two-way
repeated measures ANOVA.
RESULTS
Subject characteristics. The baseline characteristics of the
patients with CHF and controls are shown in Table 1. All
the patients with CHF were taking ACE inhibitors. Other
medications are shown in Table 1. There was no significant
difference in the age distribution between the patients with
CHF and the control group. None of the patients with
CHF was diabetic, but two were smokers; two were hyper-
tensive, and six had elevated serum cholesterol. Eight of
the patients with CHF were in atrial fibrillation. Body mass
index was 28.8 6 1.4 kg/m2 in the patients and 27.2 6
0.9 kg/m2 in the controls.
Figure 1. Typical volume/pressure relation. A 5 unstressed volume; (B-A)/A 3 100 5 % venodilation with carbachol; (C-A)/A 3 100 5 %
vasoconstriction with L-NMMA; (B-D)/(B-A) 3 100 5 % nitric oxide component of carbachol response. L-NMMA 5 N-monomethyl-L-arginine.
Table 1. Baseline Characteristics
Control Patients With CHF
Age (yrs) 60.1 (range 45 to 74) 62.2 (range 39 to 75)
Gender (M/F) 9/6 20/4
















Total cholesterol (mmol/l) 5.7 6 0.7 5.9 6 0.3
Glucose (mmol/l) 4.8 6 0.1 7.4 6 0.7
Heart rate (beats/min) 59 6 6 70 6 3
Systolic BP (mm Hg) 120 6 11 131 6 5
Diastolic BP (mm Hg) 81 6 5 77 6 3
ACE 5 angiotensin-converting enzyme; BP 5 blood pressure; CHF 5 chronic heart
failure; NYHA 5 New York Heart Association classification.
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Changes in forearm venous tone. RESTING FOREARM
VENOUS VOLUME. Mean forearm counts at rest were similar
in the patients with CHF (714 6 32 counts/s) and in the
controls (734 6 38 counts/s [p 5 NS]). The slope of the
volume/pressure relationship was 5.8 6 0.4 counts/s/mm
Hg in the patients with CHF and 6.2 6 0.9 counts/s/mm
Hg in the controls (p 5 NS).
Stimulated venous endothelial function. As shown in
Figure 2, infusion of carbachol caused a significant reduc-
tion in venous tone in controls (40.7 6 3.9%, p , 0.001)
and in patients with CHF (36.8 6 3.9%, p , 0.001). The
degree of venodilation was similar in both groups (p 5 NS).
There was no change in the slope of the volume/pressure
relation (compliance) in either group during carbachol
infusion. The maximal venodilator response to carbachol
was reduced similarly by the coinfusion of L-NMMA in
controls and in patients with CHF (% reduction in venous
tone 49.5 6 10.1% vs. 54.8 6 10.1%, p 5 NS). This
response was similar when New York Heart Association
classification (NYHA) and etiology of CHF were taken into
account (Table 2).
Basal venous NO activity. The response to L-NMMA is
illustrated in Figure 2. Infusion of L-NMMA resulted in
significant venoconstriction in both the patient (9.6 6 1.8%,
p , 0.01) and the control (6.6 6 1.7%, p , 0.01) groups.
There was no change in venous compliance in either group.
There was no difference in the degree of L-NMMA-
induced venoconstriction, that is, basal NO activity, be-
tween the patients with heart failure and the controls (9.6 6
1.8% vs. 6.6 6 1.7%, p 5 NS) nor when NYHA status and
etiology were taken into account (Table 2).
Arterial endothelial function in response to shear stress.
Flow-mediated dilation (FMD) was significantly impaired
in the patients with CHF compared with controls (% FMD
in CHF 2.0 6 0.6% vs. controls 7.5 6 2.5%, p , 0.01).
DISCUSSION
This study demonstrated that both basal and carbachol-
stimulated NO release was preserved in patients with CHF
compared with matched controls. This was in marked
contrast with the impaired endothelial response to flow-
Figure 2. Effect of carbachol and L-NMMA on venous tone. *p , 0.01 change from unstressed volume with carbachol or L-NMMA; †p , 0.01 reduction
in carbachol response with coinfusion; ‡p 5 ns compared with controls. CHF 5 chronic heart failure; L-NMMA 5 N-monomethyl-L-arginine.
Table 2. Effects of Etiology and Functional Class on Venous Endothelial Function
Control All CHF DCM IHD NYHA II NYHA III/IV
n 16 24 10 14 8 16
Mean age (yrs) 60.1 6 1.6 62.2 6 2.4* 58.1 6 4.7* 65.1 6 2.2* 61.8 6 4.1* 62.4 6 3.0*
% venodilation with carbachol 40.7 6 3.9† 36.8 6 3.9*† 39.1 6 5.8*† 35.1 6 5.5*† 36.6 6 6.6*† 36.9 6 5.1*†
% venodilation with coinfusion 22.1 6 4.8‡ 20.3 6 4.3*‡ 18.8 6 5.7*‡ 21.1 6 6.1*‡ 16.8 6 4.2*‡ 21.6 6 5.7*‡
% venodilation with L-NMMA 26.6 6 1.7† 29.6 6 1.8*† 212.5 6 2.3*† 27.6 6 2.6*† 29.5 6 2.8*† 29.6 6 2.4*†
*p 5 ns compared with controls; †p , 0.01 compared with unstressed volume; ‡p , 0.01 reduction in carbachol effect.
CHF 5 congestive heart failure; DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart disease; L-NMMA 5 N-monomethyl-L-arginine; NYHA 5 New York Heart
Association classification.
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mediated shear stress in the brachial arteries of these
patients with CHF. This observation has important impli-
cations for our understanding of the mechanism(s) that
gives rise to endothelial dysfunction in CHF. Furthermore,
our data suggest that venous endothelium has the potential
to significantly modulate venous tone, and, therefore, car-
diac filling pressures, in CHF.
Rationale for studying CHF patients on ACE inhibitors.
Our patients were all on stable therapy with ACE inhibi-
tors. These agents form the mainstay of treatment for CHF,
and it would have been unethical to withdraw them for the
period necessary for the tissue activity of these drugs to
cease. The alternative strategies for studying patients not on
ACE inhibitors would have been to recruit patients intol-
erant of ACE inhibitors or before initiation of ACE
intolerant of ACE inhibitor therapy. However, most sub-
jects intolerant of ACE inhibitors are treated with AT1
receptor antagonists, and these would have effects on an-
giotensin II and, thus, endothelial function. It would have
been possible to study subjects before initiation of ACE
inhibitors. This would also have raised difficulties in inter-
preting the results. These subjects would have been likely to
have had markedly raised venous pressures (and volumes)
compared with healthy subjects. Therefore, comparing
changes in venous volume between the two groups would
have been extremely difficult. A potential drawback of our
strategy is that ACE inhibitors are known to improve
arterial endothelial function. However, most studies in
patients on long-term ACE inhibitor therapy have shown
residual impairment of arterial endothelial function (1,3,9).
Consistent with this, the patients with CHF in this study
demonstrated marked arterial endothelial dysfunction de-
spite treatment with ACE inhibitors. Furthermore, despite
ACE inhibitor therapy, two thirds of the patients were in
class III and IV, and the venous endothelial responses did
not differ when analyzed according to NYHA functional
class.
Endothelial dysfunction in CHF. Endothelial dysfunc-
tion plays an important role in cardiovascular pathophysi-
ology and is believed to be predominantly due to reduced
NO bioavailability (25). Endothelial dysfunction has been
clearly demonstrated in both conduit arteries and resistance
vessels in CHF (1–7). In conduit arteries, such as the
brachial artery, there is a reduction in NO activity in
response to increased shear stress. This is manifest (as in the
present study) as a reduced brachial artery dilator response
to increased flow (1). Similarly, dilator responses to
endothelium-dependent agonists such as acetylcholine, bra-
dykinin and carbachol have consistently been reported as
having been reduced in the resistance vessels of patients
with CHF (2–5). These abnormalities, which are only
partially ameliorated by ACE inhibitor therapy (26), are due
to a reduction in agonist-stimulated or shear-related NO
activity. There are conflicting data as to whether basal NO
activity is reduced in the arterial circulation of patients with
CHF (3,27–30). Studies in ACE inhibitor treated patients
have generally shown preservation of basal NO activity (27),
whereas a study in untreated patients reported it to be
markedly impaired (30).
Importantly, in this study, despite a marked reduction in
brachial artery FMD, there was preservation of both basal
and stimulated NO activity in the forearm venous capaci-
tance bed of patients with CHF. One caveat is that our data
are expressed in terms of percentage change in venous tone
(or unstressed volume) from baseline. If venous capacitance
were markedly reduced in the patients with CHF, then a
similar percentage change in unstressed volume during
L-NMMA or carbachol might nevertheless reflect a re-
duced absolute response. Our data do not support this.
Forearm venous counts were similar in patients with CHF
and controls; body mass index (and, therefore, tissue atten-
uation) was actually a little higher in patients. It is, there-
fore, highly unlikely that, in this (treated) group of patients
with CHF, forearm venous volume is significantly different
between the two groups. An additional caveat must be
applied before concluding that stimulated NO activity is
preserved. We showed that the maximal vasodilator re-
sponse to carbachol was similar in patients and controls.
This does not exclude a reduced response to a submaximal
dose. However, it was not possible to examine dose-
response relations in the venous capacitance bed. A reduced
dilator response in resistance vessels in CHF would result in
lower flow rates and relatively higher carbachol concentra-
tions in venous/venular blood for a given flow rate. How-
ever, we know that, in the arterial circulation, maximal
responses to endothelium-dependent agonists are dimin-
ished (5).
Pathophysiological implications. Our observation of pre-
served agonist-mediated NO activity in the venous capaci-
tance bed, despite marked impairment of shear-related NO
release in the brachial artery, is intriguing. It might be
argued that shear stress and agonist responses might differ,
but, as noted above, agonist-mediated NO activity has also
been consistently shown to be diminished in CHF, even in
those treated with ACE inhibitors. The mechanism(s) of
endothelial dysfunction in the arterial circulation in CHF
are not fully established. It is clear that the impairment
resides in the NO component. Broadly, this may be due to
impairment in NO synthesis, reduction in NO bioavailabil-
ity (via its oxidation to peroxynitrite) or to an abnormality of
signaling pathways within smooth muscle (which may or
may not be due to increased oxidative stress) (25).
It is unclear whether NO synthesis in arteries and
arterioles is impaired in CHF. Plasma levels of asymmetric
dimethylarginine are increased in CHF (31). Asymmetric
dimethylarginine is an endogenous inhibitor of L-arginine
cellular uptake and binding to eNOS. This might be
expected to reduce NO synthesis rates. Conversely, it has
been reported that plasma nitrate may be increased in CHF
although this may be due to reduced renal excretion (32).
Oxidative stress is increased in CHF (33). Both short
lived lipid-derived free radicals and longer-lived products of
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lipid peroxidation are increased in proportion to the func-
tional severity of the CHF, and antioxidant defenses are
diminished (34–36). Increased oxidative stress may be
directly toxic to endothelium as reactive oxygen species can
combine with NO to form peroxynitrite, which has toxic
effects (37). Furthermore, reactive oxygen species may cause
signaling pathway abnormalities in vascular smooth muscle
(38). The marked improvement in endothelium-dependent
vasodilation after acute and chronic oral vitamin C admin-
istration implies an important role for oxidative stress in the
endothelial dysfunction (34,39) although recent data sug-
gest that vitamin C may also have other relevant effects (40).
What insights may the preservation of function of the
venous endothelium in CHF provide into pathophysiology?
In saphenous vein rings, eNOS messenger RNA was lower
than it was in internal mammary artery rings, arguing
against increased NO synthesis in veins (41). However,
there is no data on NO synthesis from the functionally more
important small veins and venules that we have studied.
Furthermore, asymmetrical dimethylarginine levels are in-
creased in venous as well as in arterial blood in patients with
CHF. It may seem logical that, since lipid-derived free
radicals and thiobarbituric acid reactive substances are
increased in venous blood in patients with CHF, the venous
endothelium would also be exposed to a similar degree of
oxidative stress as the arterial circulation. However, it is the
local levels of the short-lived radicals, superoxide and
hydrogen peroxide, that are relevant in terms of the under-
lying pathophysiology of endothelial dysfunction, not the
longer-lived markers of oxidative stress. A recent study
reported that saphenous vein rings demonstrated a markedly
reduced capacity to generate superoxide via the NAD(P)H
oxidase enzyme system in response to angiotensin II stim-
ulation compared with internal mammary artery rings (42).
Thus, local levels of oxidative stress may be lower in veins
than they are in arteries. While our observations do not
prove such a mechanism, they are consistent with it.
Clinical implications. On the face of it, our observation
that forearm venous capacitance was not lower in patients
with CHF than it was in controls may seem surprising. In
untreated CHF, venous tone is increased (and venous
capacitance reduced) in the same way that systemic vascular
resistance is increased (43,44). However, we know that in
patients treated with ACE inhibitors, systemic vascular
resistance falls to normal levels (44). It is, therefore, per-
fectly consistent that the same changes might occur in
venous capacitance. Indeed, in severe CHF, optimal therapy
may require a reduction in venous tone or systemic vascular
resistance to below “normal” levels (44). Therefore, our
observation that the venous endothelium is capable of
responding normally to agonists raises the potential of novel
therapy to lower venous tone. Nebivolol, for example, is a
beta-adrenergic blocking agent that has vasodilator actions
via increasing NO synthesis (45). The action of agents such
as this on venous tone in patients with CHF needs to be
tested as further reductions in venous tone might be
expected to be associated with beneficial hemodynamic
changes in certain patients with CHF. In addition, this
study raises the highly intriguing question of why venous
endothelial function is preserved despite the presence of
marked arterial endothelial dysfunction. An understanding
of the mechanisms involved may allow new strategies for
improving arterial endothelial function.
Study limitations. We cannot necessarily extrapolate our
data to other large venous capacitance beds such as the
splanchnic bed. Assessment of this bed would be highly
invasive given the need for local infusion of carbachol and
L-NMMA. As discussed above, these results need to be
interpreted in light of concurrent drug treatment including
ACE inhibitors.
Conclusions. Despite marked impairment of shear-related
NO activity in the brachial artery, both basal and agonist-
mediated NO activity were preserved in the forearm venous
capacitance bed of patients with CHF receiving treatment
with ACE inhibitors. Potential mechanism(s) for this “pro-
tection” has been discussed but remains to be determined.
Our findings have important clinical implications suggest-
ing that endothelium-dependent agonists may have the
potential to lower venous tone and, thus, improve central
hemodynamics.
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